Literature DB >> 11096576

Alcoholic Liver Disease.

.   

Abstract

The traditional approach to alcoholism is treatment of underlying psychological and behavioral problems. Earlier and more direct avenues to prevent or counteract alcohol's effects include a focus on early detection of alcoholism, using, in part, biochemical markers of heavy drinking such as carbohydrate-deficient transferrin (CDT) and screening, among heavy users of alcohol, for signs of medical complications. Only a few heavy drinkers eventually develop liver cirrhosis. Because no practical genetic markers exist indicating who will develop fibrosis and cirrhosis, heavy drinkers who have signs of liver injury should undergo liver biopsy to determine whether they have perivenular fibrosis, a recognized precursor lesion to cirrhosis. Those who do should start intense treatment efforts, such as correction of nutritional deficits, curbing alcohol consumption, and participation in ongoing controlled trials. Some "supernutrients" have been effective in baboons, including S-adenosylmethionine for the treatment of alcohol-induced liver injury and polyenylphosphatidylcholine for the prevention of fibrosis. Both drugs are now being tested in humans. Prednisolone improves survival in patients with alcoholic hepatitis who have either spontaneous hepatic encephalopathy or a high "discriminant function."

Entities:  

Year:  1999        PMID: 11096576     DOI: 10.1007/s11938-999-0022-5

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  33 in total

Review 1.  Pathogenesis and treatment of liver fibrosis in alcoholics: 1996 update.

Authors:  C S Lieber
Journal:  Dig Dis       Date:  1997 Jan-Apr       Impact factor: 2.404

2.  Alcoholic hepatitis and liver transplantation: the controversy continues.

Authors:  M F Sorrell; R K Zetterman; J P Donovan
Journal:  Alcohol Clin Exp Res       Date:  1994-04       Impact factor: 3.455

3.  Long-term treatment of alcoholic liver disease with propylthiouracil.

Authors:  H Orrego; J E Blake; L M Blendis; K V Compton; Y Israel
Journal:  N Engl J Med       Date:  1987-12-03       Impact factor: 91.245

4.  A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis.

Authors:  J Fehér; A Cornides; A Romány; M Kárteszi; L Szalay; A Gógl; J Picazo
Journal:  J Hepatol       Date:  1987-10       Impact factor: 25.083

5.  Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon.

Authors:  C S Lieber; M A Leo; S I Aleynik; M K Aleynik; L M DeCarli
Journal:  Alcohol Clin Exp Res       Date:  1997-04       Impact factor: 3.455

6.  Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon.

Authors:  C S Lieber; S J Robins; J Li; L M DeCarli; K M Mak; J M Fasulo; M A Leo
Journal:  Gastroenterology       Date:  1994-01       Impact factor: 22.682

7.  Perivenular fibrosis as precursor lesion of cirrhosis.

Authors:  T M Worner; C S Lieber
Journal:  JAMA       Date:  1985-08-02       Impact factor: 56.272

8.  Colchicine in the treatment of cirrhosis of the liver.

Authors:  D Kershenobich; F Vargas; G Garcia-Tsao; R Perez Tamayo; M Gent; M Rojkind
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

9.  S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon.

Authors:  C S Lieber; A Casini; L M DeCarli; C I Kim; N Lowe; R Sasaki; M A Leo
Journal:  Hepatology       Date:  1990-02       Impact factor: 17.425

10.  Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial.

Authors:  R L Carithers; H F Herlong; A M Diehl; E W Shaw; B Combes; H J Fallon; W C Maddrey
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

View more
  1 in total

1.  A Complex Multiherbal Regimen Based on Ayurveda Medicine for the Management of Hepatic Cirrhosis Complicated by Ascites: Nonrandomized, Uncontrolled, Single Group, Open-Label Observational Clinical Study.

Authors:  Manish V Patel; Kalapi B Patel; Shivenarain Gupta; Andreas Michalsen; Elmar Stapelfeldt; Christian S Kessler
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-03       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.